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chemotherapy and lower costs in younger patients, and slightly increased use of chemotherapy and
higher costs in older patients. Genomic testing in actual practice may “rule out” chemotherapy in younger
women, and “rule in” chemotherapy in older women.
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Journal of Clinical Oncology, December 2015
KEY FINDINGS:
Genomic testing in patients with early-stage breast cancer is associated with decreased use of chemotherapy and lower costs
in younger patients, and slightly increased use of chemotherapy and higher costs in older patients. Genomic testing in actual
practice may “rule out” chemotherapy in younger women, and “rule in” chemotherapy in older women.

THE QUESTION
The promise of personalized genomic testing is that it can
reduce unnecessary care and costs by predicting which
patients are most likely to benefit from a treatment. After
surgery, women with early-stage breast cancer face the
decision of whether to undergo expensive and potentially
toxic chemotherapy to prevent recurrence, although
most will not have a recurrence. The 21-gene recurrence
score test (RS) was developed in 2004 to predict this
risk, and its use in clinical medicine is increasing. In this
study of actual treatment patterns, LDI Senior Fellows
Andrew Epstein and Peter Groeneveld and colleagues
investigate how genomic testing of women with earlystage breast cancer affects subsequent chemotherapy
use and medical spending in the year after diagnosis.

Among women older than 75, however, RS testing
increased chemotherapy use by almost 6 percentage points
(from 8.7% to 14.4%) and increased medical spending by
more than $3,000 (from $29,720 to $33,209). The authors
found that the rate of RS testing decreased with age after 55.

THE FINDINGS
The study found that RS testing influenced treatment
decisions and medical expenses differently for younger
Source: Journal of Clinical Oncology, Dec 20, 2015
and older patients. Among women younger than 55,
Incremental effect of RS receipt on probability of receiving chemotherapy and
RS testing was associated with a nearly 20 percentage
on total spending
The gold lines represent the difference in probability (0 to 1 scale) of chemotherapy
point decrease in use of chemotherapy (from 60.8%
use among RS recipients. The blue lines represent the change in total health care
to 41.5%) and $15,000 less in medical spending in the
costs (2010 $US) among RS recipients. The vertical lines indicate 95% CIs for the
12 months after diagnosis (from $96,667 to $81,334).
point estimates.
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THE IMPLICATIONS

weighted regression models to find out whether and how RS

These findings have important policy implications for

after diagnosis.

genomic testing. In real-world practice settings, RS testing

testing influenced chemotherapy use and medical spending

was associated with substantial reductions in the use of

chemotherapy and medical spending in younger women,

implying that RS testing reduced unnecessary treatment—a
critical goal of personalized medicine. Among elderly

Epstein AJ, Wong YN, Mitra N, et al. Adjuvant Chemotherapy Use and Health
Care Costs After Introduction of Genomic Testing in Breast Cancer. JCO Dec
20, 2015:4259-4267; DOI:10.1200/JCO.2015.61.9023.

women, however, RS testing may provide impetus to use
chemotherapy among patients with comorbidities.

Hence, RS testing may be commonly used among younger
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patients to “rule out” patients for chemotherapy, but,

conversely, it may be used among older patients to “rule
in” the use of chemotherapy patients who otherwise would

not be candidates for chemotherapy due to their frailty or

comorbid conditions. At a population level, the impact of RS
testing is much greater for younger women.

THE STUDY
The authors used the Pennsylvania Cancer Registry to
assemble a cohort of 7,287 women who were diagnosed
with early-stage breast cancer between 2007 and 2010 and

had initial surgical treatment. Unlike most studies of cancer
treatment, the authors studied patients who were covered
both under Medicare (74%) and private insurance (26%).

Compared to patients who did not receive RS testing,
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patients with RS testing were younger and more likely to

have private insurance, have fewer comorbidities, and have

stage I breast cancer. The registry data were combined with
administrative claims data from traditional Medicare and
Independence Blue Cross covering 12 months before and

after diagnosis to identify patient comorbidities, treatments
and expenditures. The authors used propensity score-
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